Inclisiran (Leqvio) for LDL-Cholesterol Lowering

Date: March 21, 2022
Issue #: 
1646Summary: 
The FDA has approved inclisiran (Leqvio– Novartis),
a small interfering RNA (siRNA) directed to proprotein
convertase subtilisin/kexin type 9 (PCSK9) mRNA,
as an adjunct to diet and maximally tolerated statin
therapy for subcutaneous (SC) treatment of adults
with heterozygous familial hypercholesterolemia
(HeFH) or clinical atheroscler otic cardiovascular
disease (ASCVD) who require additional lowering
of low-density lipoprotein cholesterol (LDL-C).
Inclisiran is the first FDA-approved PCSK9-directed
siRNA therapeutic agent.

Source: The Medical Letter - February 8, 2022 Category: Drugs & Pharmacology Authors: admin Tags: alirocumab bempedoic acid evolocumab Ezetimibe Ezetrol Hypercholesterolemia inclisiran Leqvio Nexletol Nexlizet Praluent Repatha Statins Zetia Source Type: research